An Adaptive Group Sequential Phase II Design to Compare Treatments for Survival Endpoints in Rare Patient Entities

Christina Wunder, Annette Kopp-Schneider, Lutz Edler
  • Journal of Biopharmaceutical Statistics, January 2012, Taylor & Francis
  • DOI: 10.1080/10543406.2010.531831

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr Annette Kopp-Schneider